PETMEDIX

petmedix-logo

PetMedix is a development stage veterinary biopharmaceutical company based in Cambridge, UK. they are using the highest quality science to make the therapies their pets need and deserve, keeping them healthier, happier, and for longer. Building on more than thirty years of world-leading innovation and human drug development, they are applying the cutting edge of science to bring breakthroughs for the animals they love and care for.

#SimilarOrganizations #People #Financial #Website #More

PETMEDIX

Social Links:

Industry:
Biotechnology Health Care

Founded:
2017-01-01

Address:
Cambridge, Cambridgeshire, United Kingdom

Country:
United Kingdom

Website Url:
http://www.petmedix.co.uk

Total Employee:
1+

Status:
Active

Total Funding:
37 M GBP

Technology used in webpage:
SPF Domain Not Resolving Euro Google Apps For Business Google Maps OVH Google DNS Google Domains Google Cloud DNS


Similar Organizations

context-therapeutics-logo

Context Therapeutics

Context Therapeutics is a clinical-stage biopharmaceutical company.

emendo-biotherapeutics-logo

Emendo Biotherapeutics

Emendo Biotherapeutics is a biotechnology company

feel-logo

Feel

Feel is a pure nutritional supplements startup.

healthwire-logo

Healthwire

Healthwire is a health-tech startup.

caraway-therapeutics-logo

Caraway Therapeutics

Rheostat Therapeutics is a bio therapeutics company.

themis-bioscience-logo

Themis Bioscience

Themis Bioscience is a start-up biotechnology company.


Current Advisors List

cindy-cole_image

Cindy Cole Board Member @ PetMedix
Board_member

Current Employees Featured

alastair-kilgour_image

Alastair Kilgour
Alastair Kilgour Investor Director @ PetMedix
Investor Director
2019-02-01

thomas-weaver_image

Thomas Weaver
Thomas Weaver Founder & CEO @ PetMedix
Founder & CEO
2018-01-01

david-lowery_image

David Lowery
David Lowery Chief Product Development Officer @ PetMedix
Chief Product Development Officer

allan-bradley_image

Allan Bradley
Allan Bradley Chief Scientific Officer @ PetMedix
Chief Scientific Officer

jolyon-martin_image

Jolyon Martin
Jolyon Martin Head of Product & Business Development @ PetMedix
Head of Product & Business Development

Founder


allan-bradley_image

Allan Bradley

jolyon-martin_image

Jolyon Martin

thomas-weaver_image

Thomas Weaver

Investors List

parkwalk-advisors_image

Parkwalk Advisors

Parkwalk Advisors investment in Series B - PetMedix

kyoritsu-corporation_image

Kyoritsu Corporation

Kyoritsu Corporation investment in Series B - PetMedix

cambridge-innovation-capital_image

Cambridge Innovation Capital

Cambridge Innovation Capital investment in Series B - PetMedix

tencent_image

Tencent

Tencent investment in Series B - PetMedix

digitalis-ventures_image

Digitalis Ventures

Digitalis Ventures investment in Series B - PetMedix

parkwalk-advisors_image

Parkwalk Advisors

Parkwalk Advisors investment in Series A - PetMedix

digitalis-ventures_image

Digitalis Ventures

Digitalis Ventures investment in Series A - PetMedix

companion-fund_image

Companion Fund

Companion Fund investment in Series A - PetMedix

Official Site Inspections

http://www.petmedix.co.uk

Unable to get host informations!!!

Loading ...

More informations about "PetMedix"

PetMedix - Crunchbase Company Profile & Funding

PetMedix is a development stage veterinary biopharmaceutical company based in Cambridge, UK. they are using the highest quality science to make the therapies their pets need and deserve, keeping them healthier, happier, and for longer. …See details»

Member profile: PetMedix | BIA

Https://petmedix.co.uk. Membership category Corporate. The Glenn Berge Building, Babraham Research campus, Cambridge, CB22 3FH, United Kingdom. PetMedix at a glance. Antibody …See details»

PetMedix joins Zoetis to bring the benefits of species-specific ...

Sep 25, 2023 That is the whole point of our company,” commented Dr. Tom Weaver, co-founder and CEO of PetMedix. “I couldn’t be prouder of the PetMedix team’s accomplishments. ...See details»

More animal magic as Zoetis acquires PetMedix in Cambridge

Sep 18, 2023 Dr Tom Weaver, co-founder and CEO of PetMedix, said: “Today marks a new milestone as PetMedix joins forces with Zoetis, the world’s leading animal health …See details»

PetMedix Company Profile 2024: Valuation, Investors, Acquisition ...

Cambridge Innovation Capital, Digitalis Ventures, Kyoritsu Seiyaku, Parkwalk Advisors, and Tencent Holdings have invested in PetMedix. Who are PetMedix’s competitors? Boehringer …See details»

PetMedix Company Profile | Management and Employees List

[email protected]: PetMedix Top Competitors. Company Employees Revenue Top technologies; Saint-Gobain. 24: $1.7 M: Immundnz. 10: $3.6 M: Reinnervate. 99: $19.2 M: …See details»

PetMedix and Zoetis partner to develop species-specific antibody ...

Sep 5, 2024 PetMedix and Zoetis partner to develop species-specific antibody therapies for pets. PetMedix, a leader in discovering species-specific therapeutic antibodies for pets, announced …See details»

Petmedix | VentureRadar

PetMedix is utilising tried and tested antibody technology to develop treatments for diseases in companion animals. Monoclonal antibodies are now a hugely important human drug class but …See details»

PETMEDIX LTD Company Profile | BABRAHAM, United Kingdom

Find company research, competitor information, contact details & financial data for PETMEDIX LTD of BABRAHAM. Get the latest business insights from Dun & Bradstreet.See details»

PetMedix raises $37M Series B - Cambridge Innovation Capital

Sep 8, 2021 While the initial focus will be the United States, the company has built an international organisation and financing syndicate to support efforts in European and Asian …See details»

More Cambridge-US activity as PetMedix is acquired by Zoetis

Sep 27, 2023 Dr Jolyon Martin, left, co-founder and head of business development, with Dr Tom Weaver, CEO and co-founder, right. Located on Babraham Research Campus, PetMedix will …See details»

Cambridge-based PetMedix bags £27M funding to revolutionise …

PetMedix is a UK-focused biotech company that was founded in 2018. It spun out from the lab of Prof Allan Bradley FRS and is based upon the PhD work of his student, now PetMedix co …See details»

PetMedix - closes $37m Series B round - Parkwalk Advisors

Sep 8, 2021 This financing round will propel PetMedix from an R&D-stage, UK-focused biotech company, into a clinical-stage international organisation. PetMedix’s internal discovery …See details»

PetMedix raises $37M Series B / Veterinary Industry News

4 days ago This financing round will propel PetMedix from an R&D-stage, UK-focused biotech company, into a clinical-stage international organisation. PetMedix’s internal discovery …See details»

PetMedix set to transform companion animal health with …

PetMedix is looking to close the current extension to the Series A funding by Autumn 2019 and is interested in hearing from potential investment partners and M&A. Contact Jolyon Martin, …See details»

Cambridge-based PetMedix bags £27M funding to revolutionise …

Sep 8, 2021 PetMedix has now raised a notable £27 million in its series B funding round to help expand its business internationally. ... PetMedix’s co-founder Jolyon Martin says, ” These …See details»

PetMedix | London Startups

PetMedix. PetMedix is a biomedical company specializing in the development of species-specific, therapeutic antibodies for pets. The company's focus lies in leveraging its skilled scientific …See details»

PetMedix Raises $37M in Series B Funding - FinSMEs

Sep 8, 2021 PetMedix, a Cambridge UK-based animal health company, raised $37M in Series B funding. ... now PetMedix co-founder, Jolyon Martin. ... PetMedix has built an international …See details»

PetMedix raises $37M Series B - Vetreport.net

Sep 8, 2021 This financing round will propel PetMedix from an R&D-stage, UK-focused biotech company, into a clinical-stage international organisation. PetMedix’s internal discovery …See details»

PetMedix raises $37M Series B | Companion Consultancy - News

Sep 8, 2021 PetMedix™ announces today the completion of an oversubscribed $37M (£27M) Series B financing round that will be used to advance its innovative pipeline through clinical …See details»

linkstock.net © 2022. All rights reserved